CNR1 and metabolic dysfunction-associated steatotic liver disease: In this context, AM6545, a peripheral CB1R antagonist, has been studied in models of obesity-associated NAFLD, demonstrating a reversal of steatosis by improving liver and adipose tissue metabolism [92].